USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Dec 31, 2021 (est) | Sep 30, 2021 | - | $-0.26 | $-0.39 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Dec 31, 2021 (est) | Sep 30, 2021 | - | $0.00 | $0.00 |
Biondvax Pharmaceuticals's next estimated earnings date (based on same quarter last year's date) is Dec 31, 2021 for the fiscal quarter ending Sep 30, 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 27, 2021 | Jun 2021 | - | $-0.26 | - |
| Jun 30, 2021 | Mar 2021 | - | $-0.26 | - |
| Mar 31, 2021 | Dec 2020 | $-0.01 | $-0.18 | -1745.00% |
| Dec 31, 2020 | Sep 2020 | - | $-0.39 | - |
| Aug 20, 2020 | Jun 2020 | $-0.01 | $-0.03 | -194.00% |
| Jun 12, 2020 | Mar 2020 | $-0.01 | $-0.03 | -190.00% |
| Nov 26, 2019 | Sep 2019 | $-0.03 | $-0.01 | 52.00% |
| Aug 28, 2019 | Jun 2019 | $-0.02 | $-0.05 | -155.50% |
| Apr 30, 2019 | Mar 2019 | $-0.01 | $-0.04 | -289.00% |
| Dec 31, 2018 | Dec 2018 | $-0.01 | $-0.05 | -400.00% |
| Nov 13, 2018 | Sep 2018 | $-0.01 | $-0.00 | 73.00% |
| Aug 22, 2018 | Jun 2018 | - | $-1.09 | - |
| May 29, 2018 | Mar 2018 | - | $-0.01 | - |
| Nov 28, 2017 | Sep 2017 | $-0.19 | $0.11 | 160.16% |
| Aug 31, 2017 | Jun 2017 | - | $-0.78 | - |
| Apr 28, 2017 | Mar 2017 | $-0.01 | $-0.18 | -1700.00% |
| Nov 28, 2016 | Sep 2016 | $-0.01 | $-0.01 | - |
| Aug 18, 2016 | Jun 2016 | - | $-0.20 | - |
| Apr 27, 2016 | Mar 2016 | $-0.09 | $-0.25 | -177.78% |
| Nov 9, 2015 | Sep 2015 | $-0.11 | $0.01 | 109.09% |
| Aug 10, 2015 | Jun 2015 | $-0.12 | $-0.14 | -16.67% |
| May 15, 2015 | Mar 2015 | - | $-0.35 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 31, 2021 | Dec 2020 | $0.00 | $-0.74 | - |
| Dec 31, 2018 | Dec 2018 | $-0.09 | $-2.94 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 27, 2021 | Jun 2021 | - | $0.00 | - |
| Jun 30, 2021 | Mar 2021 | - | $0.00 | - |
| Mar 31, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Dec 31, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 20, 2020 | Jun 2020 | - | $0.00 | - |
| Jun 12, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Nov 26, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 28, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| Apr 30, 2019 | Mar 2019 | $0.00 | $0.00 | - |
| Dec 31, 2018 | Dec 2018 | - | $0.00 | - |
| Nov 13, 2018 | Sep 2018 | - | $0.00 | - |
| Aug 22, 2018 | Jun 2018 | - | $0.00 | - |
| May 29, 2018 | Mar 2018 | $0.00 | $0.00 | - |
| Nov 28, 2017 | Sep 2017 | - | $0.00 | - |
| Aug 31, 2017 | Jun 2017 | - | $0.00 | - |
| Apr 28, 2017 | Mar 2017 | - | $0.00 | - |
| Nov 28, 2016 | Sep 2016 | - | $0.00 | - |
| Aug 18, 2016 | Jun 2016 | - | $0.00 | - |
| Apr 27, 2016 | Mar 2016 | - | $0.00 | - |
| Nov 9, 2015 | Sep 2015 | - | $0.00 | - |
| Aug 10, 2015 | Jun 2015 | - | $0.00 | - |
| May 15, 2015 | Mar 2015 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 31, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Dec 31, 2018 | Dec 2018 | $0.00 | $0.00 | - |
BVXV's next estimated earnings date (based on same quarter last year's report date) is Dec 31, 2021 for the fiscal quarter ending Sep 30, 2021.
Biondvax Pharmaceuticals's previous earnings date was Aug 27, 2021 for its fiscal quarter ended Jun 30, 2021.
BVXV's earnings per share (EPS) was $-0.26.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -0.04%, and lower than the same period a year before (Jun 2020) by 772.79%.
Revenues were $0.00.
The company reported a net income of $-11.99M.BVXV ended the quarter with $71.06M in total debt, an increase of 3.04% compared to the previous quarter, and a decrease of -42.10% compared to the same quarter a year before.
Biondvax Pharmaceuticals's previous annual earnings date was Mar 31, 2021 for its fiscal year ended Dec 31, 2020.
BVXV's earnings per share (EPS) was $-0.74.
Revenues were $0.00.
The company reported a net income of $-4.46M.
Biondvax Pharmaceuticals reported a free cash flow of $-78.67M for its fiscal year, compared to $-84.49M a year ago.
The company ended the fiscal year with $67.16M in total debt, a decrease of -48.84% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
